Navigation Links
Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
Date:4/28/2008

a useful adjunct to

current methods for prostate cancer diagnosis. The researchers found

that PCA3 scores correlate with the probability of positive prostate

biopsies, and that PCA3 scores are independent of prostate volume,

serum PSA level and number of prior biopsies. In the second article,

"PCA3 Molecular Urine Assay Correlates With Prostate Cancer Tumor

Volume: Implication in Selecting Candidates for Active Surveillance"

(Volume 179, Issue 5, Pages 1804-1810, May 2008), researchers from the

MD Anderson Cancer Center and Gen-Probe conclude that PCA3 scores

correlate with both tumor volumes and prostatectomy Gleason scores,

both of which are measures of prostate cancer aggressiveness. As a

result, they suggest that PCA3 may have clinical applicability in

identifying men who have low-volume or low-grade prostate cancer.

Webcast Conference Call

A live webcast of Gen-Probe's first quarter 2008 conference call for investors can be accessed at http://www.gen-probe.com beginning at 4:30 p.m. Eastern Time today. The webcast will be archived for at least 90 days. A telephone replay of the call also will be available for approximately 24 hours. The replay number is (866) 421-6934 for domestic callers and (203) 369-0825 for international callers.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more i
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
2. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
3. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
4. Carl Hull Named President and Chief Operating Officer of Gen-Probe
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
6. Gen-Probe to Webcast Three Upcoming Presentations
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
9. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
10. CV Therapeutics Reports 2008 First Quarter Financial Results
11. Caliper Life Sciences Reports West Coast Consolidation of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Type 2 diabetes gene predisposes children to obesity 2Springer signs co-publishing agreement with the Royal Swedish Academy of Sciences 2New understanding of how to prevent destruction of a tumor suppressor 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues 3B Improved Bottom Line 14741 1ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues 3B Improved Bottom Line 14741 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues 3B Improved Bottom Line 14741 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues 3B Improved Bottom Line 14741 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues 3B Improved Bottom Line 14741 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues 3B Improved Bottom Line 14741 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues 3B Improved Bottom Line 14741 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues 3B Improved Bottom Line 14741 8ARKRAY Inc Receives FDA Clearance for New GLUCOCARD 28R 29 Vital 28TM 29 Blood Glucose Monitoring System 6035 1ARKRAY Inc Receives FDA Clearance for New GLUCOCARD 28R 29 Vital 28TM 29 Blood Glucose Monitoring System 6035 2ResMed Inc Announces Record Financial Results for the Quarter Ended September 30 2009 6030 1ResMed Inc Announces Record Financial Results for the Quarter Ended September 30 2009 6030 2ResMed Inc Announces Record Financial Results for the Quarter Ended September 30 2009 6030 3ResMed Inc Announces Record Financial Results for the Quarter Ended September 30 2009 6030 4ResMed Inc Announces Record Financial Results for the Quarter Ended September 30 2009 6030 5ResMed Inc Announces Record Financial Results for the Quarter Ended September 30 2009 6030 6ResMed Inc Announces Record Financial Results for the Quarter Ended September 30 2009 6030 7